Ask AI
ProCE Banner Activity

IMforte: Phase III Trial of Lurbinectedin + Atezolizumab vs Atezolizumab as First-line Maintenance Therapy in ES-SCLC

Conference Coverage
Slideset

In the phase III IMforte trial, first-line maintenance therapy with lurbinectedin + atezolizumab vs atezolizumab in patients with ES-SCLC and CR/PR/SD to induction therapy was associated with a meaningful improvement in IRF-PFS and OS, with a consistent safety profile for lurbinectedin + atezolizumab and no new safety signals.

Released: June 05, 2025

Expiration: December 04, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar